Recent Press Releases

Health Care Equities Movers and Shakers -- Research on Quintiles Transnational, PerkinElmer, PAREXEL Intl., and Charles River Laboratories Intl.

Editor Note: For more information about this release, please scroll to bottom.

LONDON, March 25, 2014

Phase 3 Pivotal Data On Amgen's Novel Investigational Cholesterol-Lowering Medicine To Be Featured At The American College of Cardiology's 63rd Annual Scientific Session

Five Phase 3 Studies With Evolocumab (AMG 145) to be Featured in Late-Breaking and Clinical Research Presentations - Data Form the Basis of Global Filing Plan

New Product Offerings, Development and Research Collaboration, Upcoming Investor Conference, and Board Election - Analyst Notes on CVS Caremark, Teva, Zoetis, McKesson, and Mylan

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, March 24, 2014

Genzyme's Lemtrada™ Approved in Brazil for Treatment of Multiple Sclerosis

Genzyme's Lemtrada™ Approved in Brazil for Treatment of Multiple Sclerosis CAMBRIDGE, Mass., Mar 21, 2014 (BUSINESS WIRE) -- Genzyme, a Sanofi company , announced today that Brazil's...

The U.S. Food and Drug Administration today approved Otezla (apremilast) to treat adults with active psoriatic arthritis (PsA)

The U.S. Food and Drug Administration today approved Otezla (apremilast) to treat adults with active psoriatic arthritis (PsA) For Immediate Release: March 21, 2014 Media Inquiries: Morgan Liscinsky,...

Novartis announces US FDA approval of Xolair® for chronic idiopathic urticaria (CIU)

Novartis announces US FDA approval of Xolair® for chronic idiopathic urticaria (CIU) Xolair® (omalizumab) is the first and only licensed therapy in the US for the nearly 50% of patients with...

Forxiga Receives Regulatory Approval in Japan for the Treatment of Type 2 Diabetes

Forxiga Receives Regulatory Approval in Japan for the Treatment of Type 2 Diabetes 24 March 2014 AstraZeneca today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved...

CHMP Recommends Empagliflozin for Approval to Reduce Blood Sugar Levels in Adults with Type 2 Diabetes in Europe

Positive opinion is based on data from one of the largest clinical registration programs in its class, involving more than 13,000 adults with type 2 diabetes

Lupin launches Generic Niaspan® Tablets in the US

Lupin launches Generic Niaspan® Tablets in the US Mumbai, Baltimore, March 21, 2014: Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals Inc. has...

Type 2 Diabetes: CHMP recommends empagliflozin* for approval

Type 2 Diabetes: CHMP recommends empagliflozin* for approval Positive opinion for investigational SGLT2 inhibitor empagliflozin for the treatment of T2D in adults Ingelheim, Germany and...

Janssen Investigational Treatment for Schizophrenia Shows Positive Efficacy, Delays Relapse

Independent Data Monitoring Committee Recommends Halting Trial and Unblinding Data Based on Treatment Efficacy

TITUSVILLE, N.J., <

Novartis introduces Lucentis® in state of the art pre-filled syringe

Novartis introduces Lucentis® in state of the art pre-filled syringe Novartis announces the launch in Europe of the Lucentis pre-filled syringe (PFS), which is specifically designed for...

AstraZeneca Proposes Appointment of Ann Cairns as Non-Executive Director

AstraZeneca Proposes Appointment of Ann Cairns as Non-Executive Director 20 March 2014 AstraZeneca today announced that Ann Cairns will be proposed to shareholders for election as a Non-Executive...

AstraZeneca Launches Nexium® (Esomeprazole Magnesium) Direct-to-Patient Program

AstraZeneca Launches Nexium® (Esomeprazole Magnesium) Direct-to-Patient Program WILMINGTON, Del., March 19, 2014 – AstraZeneca today launched NEXIUM Direct, a program that provides eligible...

Adverseevents Debunks Previously Accepted Limitation in the Use of Faers Data for Monitoring Drug Safety

Adverseevents Debunks Previously Accepted Limitation in the Use of Faers Data for Monitoring Drug Safety Broad Research Study Published in DRUG SAFETY Refutes the 'Weber Effect' Santa Rosa,...

Tamiflu (R) reduces risk of death by 25% in adults hospitalised with H1N1 pandemic influenza

Tamiflu (R) reduces risk of death by 25% in adults hospitalised with H1N1 pandemic influenza Adults hospitalised with H1N1 influenza during the 2009–2010 pandemic were 25% less likely to die...

Horizon Pharma to Acquire Vidara Therapeutics International Ltd. and Become Horizon Pharma plc

Horizon Pharma to Acquire Vidara Therapeutics International Ltd. and Become Horizon Pharma plc Accelerates Horizon's Transformation to a Profitable Specialty Pharma CompanyExpected Pro Forma...

Astellas and Medivation Submit Supplemental New Drug Application for XTANDI (Enzalutamide) for Chemotherapy-Naive Advanced Prostate Cancer

Astellas and Medivation Submit Supplemental New Drug Application for XTANDI (Enzalutamide) for Chemotherapy-Naive Advanced Prostate Cancer TOKYO, JAPAN and SAN FRANCISCO, CA -- (Marketwired) --...

Ipsen announces positive results from phase IIa clinical study of Dysport® in the treatment of patients with Neurogenic Detrusor Overactivity (NDO)

Ipsen announces positive results from phase IIa clinical study of Dysport® in the treatment of patients with Neurogenic Detrusor Overactivity (NDO) Results show significant decrease in urinary...